Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Roma La Sapienza |
---|---|
Information provided by: | University of Roma La Sapienza |
ClinicalTrials.gov Identifier: | NCT00481572 |
The purpose of this study is to determine whether: A)the continuous infusion ultra-low dose of terlipressin (1.3 micrograms/kg/h) is able to stabilize hemodynamic in patients with septic shock, reducing the risk of adverse effects related to the bolus dose.B)the continuous infusion ultra-low dose of terlipressin may be use in lieu of vasopressin.
Condition | Intervention | Phase |
---|---|---|
Septic Shock |
Drug: Terlipressin Drug: Vasopressin Drug: Norepinephrine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study |
Official Title: | Continuous Terlipressin Versus Vasopressin Infusion in Septic Shock. A Randomized, Controlled, Pilot Trial. "THE TERLIVAP STUDY" |
Enrollment: | 45 |
Study Start Date: | January 2007 |
Study Completion Date: | December 2007 |
Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Terlipressin
|
Drug: Terlipressin
continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
|
2: Experimental
Vasopressin
|
Drug: Vasopressin
continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
|
3: Active Comparator
titrated norepinephrine
|
Drug: Norepinephrine
titrated norepinephrine over a period of 48 hrs
|
Forty-five septic shock patients requiring vasopressor support to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation were enrolled in the study. Patients were randomly allocated to be treated with either a) a continuous terlipressin infusion (1.3 µg•kg-1), b) vasopressin (0.03 U•min-1), or c) titrated norepinephrine (control; each n = 15). In both the terlipressin and vasopressin group, norepinephrine was additionally administered to achieve a mean arterial pressure (MAP) between 65 and 75 mmHg, if necessary. Data from right heart catheterization, thermo-dye dilution catheter, gastric tonometry as well as data from organ function, cytokines concentrations, were obtained at baseline and after 12, 24, 36 and 48 hours.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Italy | |
Department of Anesthesiology and Intensive care of the University of Rome "La Sapienza" | |
Rome, Viale del Policlinico 155, Italy, 00161 |
Study Director: | Andrea Morelli, MD | Departement of Anesthesiology and Intensive Care of the University of Rome "La Sapienza" |
Responsible Party: | University of Roma "La Sapienza" ( Andrea Morelli ) |
Study ID Numbers: | 1124 |
Study First Received: | May 30, 2007 |
Last Updated: | February 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00481572 |
Health Authority: | Italy: Ethics Committee |
Sepsis Septic Shock vasopressin terlipressin |
Arginine Vasopressin Systemic Inflammatory Response Syndrome Sepsis Shock Norepinephrine |
Terlipressin Shock, Septic Vasopressins Inflammation |
Neurotransmitter Agents Adrenergic alpha-Agonists Molecular Mechanisms of Pharmacological Action Adrenergic Agents Coagulants Sympathomimetics Hematologic Agents Physiological Effects of Drugs Cardiovascular Agents Antihypertensive Agents Infection |
Adrenergic Agonists Hemostatics Pharmacologic Actions Pathologic Processes Autonomic Agents Natriuretic Agents Therapeutic Uses Vasoconstrictor Agents Peripheral Nervous System Agents Antidiuretic Agents |